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Abstract
BRIDGING THE GAP: USING THE THEORY OF PLANNED BEHAVIOR TO PREDICT
HPV VACCINATION INTENTIONS IN MEN
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A thesis submitted in partial fulfillment of the requirement of the degree of Master of Science at
Virginia Commonwealth University

Virginia Commonwealth University, 2013
Major Director: Eric G. Benotsch, Ph.D
Associate Professor of Psychology
Department of Psychology
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March, 2013
Genital human papillomavirus (HPV) is the most common sexually transmitted infection
(STI) in the US, with an estimated incidence rate of 6.2 million new cases each year. Men have
higher instances of certain HPV related outcomes (e.g., head/neck cancers) when compared to
women, so male vaccination with the HPV vaccine is also paramount to preventing cancer. The
present study examined the theory of planned behavior (TPB) as a model for predicting HPV
vaccination intentions among men. Results suggest the TPB was a well-fitting model to the data,
but not all aspects of the TPB model were predictive of HPV vaccination intentions. Behavioral
beliefs (e.g.., the belief that vaccination will provide a beneficial outcome) were the only
significant predictor of HPV vaccination intention in the next 6 months. Perceived norms,
motivations to comply with norms, attitudes towards the HPV vaccine, and self-efficacy were
not significant predictors of HPV vaccination intentions.

Bridging the gap: Using the theory of planned behavior to predict HPV vaccination intentions in
men

Genital human papillomavirus (HPV) is the most common sexually transmitted infection
(STI; CDC, 2011a), with an incidence rate of approximately 6.2 million new cases each year in
the United States (Weinstock et al., 2004). HPV is part of the papillomaviridae family of viruses,
which affect all parts of the body. For instance, HPV type 1 affects the soles of the feet
primarily. Over 100 strains of HPV have been identified, with around 40 causing warts (Koutsky
& Kiviat, 1999). In general, HPV is a virus that replicates deep within the epidermis, creating
small tumors called “papillomas”. Certain strains are more of a public health concern than others,
as HPV strains 6 and 11 cause 90% of genital warts, while strains 16 and 18 can cause cervical,
anal, penile, oropharyngeal, and head/neck cancers (Markowitz et al., 2009; CDC, 2011b; Pisani
et al., 1997; Koutsky, 1997; Kreimer et al., 2005). HPV does not cause immediate symptoms
(CDC, 2011a), and as such can go unnoticed until more serious symptoms (genital warts and/or
cancer) become apparent (CDC, 2011a).
High-risk strains of HPV can be transmitted sexually, and condoms may not be very
effective in preventing HPV infection (Schiffman & Kjaer, 2003). HPV can be transmitted
through vaginal, anal and oral sex, as well as genital to genital contact (CDC, 2009). High-risk
strains (e.g., HPV strains 16 and 18) are found in 99% of cervical cancers (Bosch & de Sanjose,
2003). Genital HPV infection may cause other forms of cancers, as it has been linked with breast
cancer (Antonsson et al., 2011) and lung cancer (Li et al., 2011). It is estimated that at least 50%
of sexually active individuals have contracted one or more strains of HPV at some point in their
lives (CDC, 2011b).

1

HPV is estimated to account for about 5% of all cancers world-wide (Parkin, 2006). The
National Cancer Institute (NCI) estimates that 12,170 new cases of cervical cancer arise each
year, with around 4,220 associated deaths (NCI, 2012a). There are an estimated 5,820 new cases
of anal cancer each year, with an estimated death rate of 770 persons per year (NCI, 2011a).
Penile cancer has an incidence rate of 1,570 new cases each year, and a death rate of 310 persons
per year (NCI, 2012b). Finally, oropharangeal cancers (laryngeal and pharyngeal) have a larger
public health impact, with incidence rates estimated at 26,320 new cases yearly and an estimated
death rate of 5,990 individuals yearly (NCI, 2011b). These cancers have all been related to HPV
infection from strains 16 and 18, which underscore the importance of HPV prevention through
vaccination.
There is no approved test for HPV status in the United States for either men or women
(CDC, 2011b). This does not mean that HPV cannot be detected, it only illustrates that the CDC
and FDA have not come to a conclusion on an appropriate test for overall HPV infection.
Women’s health checks routinely require a Babeș-Papanicolaou (pap) test, by which a trained
professional inspects the cervix and takes a sample of the cells inside the cervix
(Womenshealth.gov, 2009). Pap tests in women simply screen for abnormal cells on the cervix
(Womenshealth.gov, 2009), which are primarily caused by HPV (CDC, 2011b). This provides an
indirect test for HPV, but cannot causally attribute any abnormal cells to HPV infection. Pap
tests may also not detect HPV infection, as pap tests tend to sample from the top layer of the
cervix, and might not detect lower viral load infections in the basal layer of the skin (Trotteir et
al., 2010). For men, there is not a comparable indirect test for HPV infection. There are generally
two methods employed by biological studies that assess HPV infection: seroprevalence through
antibody detection (Dunne et al., 2006), and Polymerase Chain Reaction (PCR) tests to detect the
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presence of the HPV virus itself (Dunne et al., 2006). These studies provide important
information about factors associated with HPV infection.
Seroprevalence studies show that women tend to have higher antibodies for HPV strains
6, 11, 16, and 18 when tested for HPV (Carter et al., 2001; Eisemann et al., 1996; Slavinsky et
al., 2001; Strickler et al., 1999; Svare et al., 1997; Stone et al., 2002; Thompson et al., 2004;
Kreimer et al., 2004). While not as high as their female counterparts, men also have relatively
high rates of HPV. A review by Dunne and colleagues (2006) illustrated that HPV prevalence in
men ranges from 20% to as high as 72.9% while the range for women is 14% to 90%. These
studies illustrate how highly variable HPV infection is, and this can be attributed to HPV not
being a permanent affliction. This variability could potentially be due to the variability in testing
for men and women, as well as the inefficiency of those testing methods (Trottier et al., 2010).
As HPV is an area specific infection much like the herpes-simplex virus, it is often overlooked
that men need multiple area sampling (e.g., the glans of the penis, the anus, the mouth, the
central sulcus) to detect actual HPV infection. Many cross-sectional studies that assess HPV
infection test men from one infection site (e.g., the glans of the penis), which can severely
underestimate prevalence rates among men (Giuliano et al., 2007).
HPV infections may clear from the body within a few years for those with healthy
immune systems (CDC, 2011a). Similar to common influenza and sinus infections, HPV may
eventually go away without treatment (CDC, 2011b). This assertion is not without contention.
HPV is still a relatively “new” virus in the research literature, and testing for HPV is still
inefficient (Trottier et al., 2010). Even with the highly sensitive PCR testing available, it has
been suggested that HPV may also be a latent virus (Trottier et al., 2010). A latent virus lies
dormant within a cell and can begin reproducing at any time, typically when the immune system
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is weakened. Trottier and colleagues (2010) warn that HPV viral load may fall below that which
is detectable by seroprevalence tests. This may make it appear that HPV is cleared from the
body, while it may just be that the virus has gone dormant and, therefore, undetectable. Research
supports the former hypothesis that HPV can be cleared completely from the body. Trottier and
colleagues (2010) followed women over time, testing for HPV infection and measuring sexual
behavior. Results of this study showed that women can be re-infected by the same strain of HPV
over time, and the chief proximal factor to the infection was having a new sexual partner, and
potentially being re-exposed to HPV. Furthermore, the viral loads for re-infection with the same
HPV strains were similar at both time points, suggesting that natural immunity after initial
infection did not diminish the viral burden in succeeding infections later in life (Trottier et al.,
2010). If the latent virus hypothesis were true, it would be unlikely that a new sexual partner
would potentially “re-activate” the virus, and viral loads for reactivation should not be similar to
initial infection viral loads. As stated earlier, immune changes would be a more plausible trigger
for reactivation if HPV were a latent virus.
This potentially runs contrary to how the immune system is seen to work. Cell-mediated
immunity should produce memory cells that will respond to the same strain of a pathogen if the
body becomes re-infected. This long held belief might not be entirely correct; the immune
system may react differently to chronic vs. acute viral infections. Wheery and colleagues (2004)
showed that immune T cells that respond to chronic viral infections do not gain the same
memory capabilities as do T cells that respond to acute viral infections. Wherry and colleagues
(2004) suggest that “prolonged exposure to antigen without any rest results in cells that are
“addicted “ to antigen and cannot persist without it” (p.16008). Antigen independent cells do not
develop as a result of infection, which creates poor recall of responsiveness, no homeostatic
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proliferation, and poor antigen-independent persistence when one is re-infected. This can explain
why people lose immunity to chronic viruses, and potentially explains why HPV can be reacquired multiple times. The Gardasil vaccine produces antigen independent memory cells, and
therefore potentially provides lifetime immunity against HPV strains 6, 11, 16, and 18 once the 3
shot Gardasil series is completed.
HPV can be transmitted in many ways that are not isolated to transmission through blood
contact, and condoms only offer partial protection for the sexual transmission of HPV
(Schiffman & Kjaer, 2003). Even if a condom is worn, HPV can infect areas around the penis
that are not covered by a condom (CDC, 2011a). HPV can survive outside the body for a period
of days and maintain high infectivity (Roden et al., 1997), leaving the potential risk for infection
from non-sexual contact. In fact, oral HPV transmission may be quite common because of this.
Prevention of HPV is essential considering the contagiousness of the virus. The cancer risk from
HPV is likely due to consistent re-infection of high-risk strains (e.g., strains 16 or 18; Bendik et
al., 2011; Marek et al., 2011). What potentially occurs over the course of an individual’s lifetime
is that they comes in contact with the same, or different, high-risk strains of HPV and potentially
develop HPV-related cancers as an outcome.
As the cancer risk associated with HPV infection is clear, the FDA approved a
quadrivalent vaccine (Gardasil) produced by Merck & co., Inc. to provide immunological
protection from HPV strains 6, 11, 16 and 18 in persons 9 through 26 years old on June 8, 2006
(FDA, 2010; FDA, 2006). Cervarix is an additional vaccine that has been approved to prevent
HPV. Cervarix protects against two cancer-causing strains of HPV (strains 16 and 18). This
vaccine is only marketed for girls between the ages of 9 to 25 (FDA, 2011).
HPV Vaccine Efficacy.
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Vaccines are an excellent strategy for reducing, and potentially eradicating, infectious
diseases (Andre et al., 2008). On October 21, 2009, the Advisory Committee on Immunization
Practices (ACIP) provided a passive recommendation for males between the ages of 9 and 26 to
be vaccinated with the quadrivalent HPV vaccine Gardasil, but suggested that the vaccine not be
part of routine vaccinations for men (CDC, 2010b). The intent of male vaccination, according to
the CDC, is to prevent genital warts and subsequent female infection (CDC, 2010b). The
Gardasil vaccine is taken in a 3 shot series, after the initial dose, the vaccinated individual is
asked to return 2 months later for a second dose, and again for a third dose 6 months from the
initial first dose date (Merck, 2011). Vaccination with Gardasil should start early, before an
individual sexually contracts HPV (CDC, 2011b). While ideal to be vaccinated younger, the
vaccine is still suggested for individuals up to ages 26 (CDC, 2011b). As stated earlier, the virus
is cleared in about 2 years in healthy adults (CDC, 2011b). Owing to this, it is still considered to
be effective to become vaccinated with Gardasil after sexual intercourse has been initiated (CDC,
2011b). The Gardasil vaccine has been shown to be effective in men, and it can reduce more than
90% of genital warts, as well as greater than 90% of persistent complications, including cancers,
that are caused by HPV types 6, 11, 16, and 18 (Giuliano & Palefsky, 2008).
Gardasil has been shown to be an effective vaccine for prevention of HPV viruses 6, 11,
16, and 18 (Giuliano, Palefsky, & Goldstone et al., 2011). Studies have illustrated the overall
effectiveness of Gardasil as well as its effectiveness in men (Giuliano, Palefsky, & Goldstone et
al., 2011). Long-term effectiveness is currently unknown, but research suggests lifetime
immunity as a result of full vaccination with Gardasil (CDC, 2011d).
Harm rates associated with Gardasil are relatively low. Harm rates are defined as any
harmful event that occurs after a Gardasil vaccine is administered. There are two general
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classifications of harm, those that are non-serious (e.g., headache, nausea, fainting after
injection) and those that are serious (e.g., death, permanent disability, life-threatening illness).
These reports are tracked through the Vaccine Adverse Effects Reporting System (VAERS) and
reviewed by both the FDA and the CDC. These reports are not limited to complications
immediately following vaccination, but encompass any negative consequence perceived by the
individual to be causally attributed to the vaccine administered at any time after the vaccine was
received. From 2006 to December 2008, 23 million individuals were vaccinated with Gardasil
(CDC, 2011c). Of those 23 million, 12,424 individuals reported side effects to VAERS, of which
94% were considered non-serious (CDC, 2011c). The remaining 772 cases (6% of total reports)
consisted of serious side effects, including 32 deaths (CDC, 2011c). The deaths reported to
VAERS were all explained by factors unrelated to vaccination, suggesting that they were not
causally related to receiving the Gardasil vaccination (CDC, 2011c); this further illustrates the
safety of the Gardasil vaccine.
Cost effectiveness analyses are often employed to justify the use of vaccinations. The
simple paradigm of cost-effectiveness is that if a sufficient amount of cost is expended to prevent
enough individuals from acquiring a disease, and the cost of the expenditure is greater than the
cost of treatment of that disease, then that expenditure is considered cost effective. As applied to
HPV vaccination, does it simply cost less to vaccinate a group of people than it is to pay for
treatment? The CDC has, for now, decided that it is only cost effective to strongly suggest
vaccinations of women against HPV (CDC, 2010c). The goal of solely vaccinating women is that
if women are vaccinated, then HPV related cancers will largely be prevented, and this will also
protect heterosexual men from infection.
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However, for the most part, vaccinating men has also been consistently shown to be cost
effective (Elbasha & Dasbach, 2010; Chesson et al., 2011; Kreimer & Chaturvedi, 2011). While
most literature strongly supports HPV vaccination in men (e.g., Elbasha & Dasbach, 2010,
Kreimer & Chaturvedi, 2011), Chesson and associates (2011) suggest that vaccination of men
may not be cost effective if vaccine uptake among women is above 80%. There are two problems
with this assertion. Firstly, it ignores the social aspect of HPV vaccination and the hesitation of
some mothers to vaccinate their child with a vaccine that prevents an STI (Gordon et al., 2011),
which may reduce vaccine uptake in the population of women. Giuliano & Salmon (2008) argue
that vaccination of men with Gardasil will become inevitable, as the current program of
mandated vaccines for one gender fails to adequately control the spread of HPV due to less than
desirable amounts of uptake among girls and women in the population. There are no current
population estimates that illustrate the actual uptake percentage of the HPV vaccine by women,
but a review of the literature on HPV vaccine uptake among women revealed a low estimate of
37%; Bartlett et al., 2011). This estimate is much lower than the suggested 80% uptake among
women to make male vaccination not cost effective (Chesson et al., 2011). This approach also
ignores the sexual experiences of men who have sex with men (MSM; Gilbert et al., 2011b), as
they are left completely unprotected in a theoretical situation whereby all women are potentially
vaccinated.
Lessons Learned From Gendered Vaccination Programs
The NCI predicts that there will be 12,170 new cases of cervical cancer in 2012, with
4,220 associated deaths (NCI, 2012c). Cervical cancer is almost always caused by HPV (NCI,
2012c), but it is not the only cancer that is highly associated with HPV. Almost all anal cancers
are caused by HPV, and a large portion of oropharyngeal and penile cancers are causally related
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to HPV infection (Parkin & Bray, 2006; Watson et al., 2008); these cancers, however, can infect
both sexes.
Vaccination programs that have targeted only one gender have generally failed. Out of 75
countries who used the rubella vaccine in 1996, 9% of those countries selectively immunized
women (Robertson et al., 1997). In the United Kingdom, the rubella vaccine was solely given to
young girls, caregivers, and at-risk older women. The weakness of this approach became evident
in 1996 when the rubella virus resurged as a result of susceptibility among men (Tookey et al.,
1999; Vyse et al., 2002). It is therefore argued that any viral eradication effort must include both
genders. Vaccinating men has the independent benefit of protecting men from HPV related
cancers, but can also aid in the prevention of cervical cancer in women. The rubella virus is
fundamentally different from HPV in that it is not sexually transmitted, and not typically serious.
However, considering how contagious HPV is, a similar pattern of resurgence is potentially
possible.
HPV and Men.
Why Study HPV in Men?
Whereas women have a higher incidence of some HPV related cancers than men, the
vaccine is passively suggested to be given to males ages 9 through 26 to prevent genital warts
(CDC, 2010b; CDC 2011b). Every year in the United States, there are an average of 400 men
who are diagnosed with HPV-related penile cancer, 1,500 men are diagnosed with HPV-related
anal cancer, and 5,600 men each year are diagnosed with oropharyngeal cancers (CDC, 2011a).
While the penile cancer rate is low and rare, it has a very high mortality rate associated with
infection (Giuliano et al., 2010). Almost half of all penile cancers are estimated to be due to HPV
infection (Parkin & Bray, 2006), and men have higher incidences of every type of oral HPV-
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related cancer than do women (CDC, 2011a). Oropharyngeal cancer incidences have decreased
slightly over time, with a stronger decrease for women than for men (NCI, 2011c). Even with
overall oropharyngeal cancer rates decreasing, men still have higher overall incidences of
oropharyngeal cancers than women (NCI, 2011c). Further, men have a higher mortality rate
associated with oropharyngeal cancers than do women (NCI, 2011c). This further illustrates that
women are not the sole risk group for cancerous HPV related outcomes.
Anal cancer trends continue to increase for men and women, with men having shown
greater increases in anal cancer morbidity than women over time (NCI, 2011b). Anal cancers
among men in the US have gone from 0.5 per 100,000 in 1974 to 1.4 per 100,000 in 2008 (NCI,
2011b). There have been statistically significant trend increases in anal cancers over time for
both men and women over the past 33 years, but these incidences of anal cancer among men are
greater than those among women (NCI, 2011b). Considering the high mortality rate associated
with penile cancer, the increases in male anal cancer, and the large gender differences in
oropharyngeal cancer rates, prevention efforts need to be aimed at men as well as women.
Genital Warts
Cancer is not the only risk associated with HPV. While strains 16 and 18 are causally
related to cancer, strains 6 and 11 are causally attributed to genital warts (CDC, 2011a). Genital
warts in themselves can cause negative outcomes. For instance, a study by Smith and colleagues
(2010) illustrated that men with HPV in Kenya were almost twice as likely to later contract HIV.
The authors suggest that genital warts may be a potential reason for this, as the inflammation
caused by genital warts may weaken the natural skin barrier and increase likelihood of HIV
transmission (Smith et al., 2010).
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Genital warts tend to occur approximately 3 to 6 months after initial infection, but can
stay dormant in the host for years before any manifestations of warts occur (Persson et al., 1993;
Clarke et al., 1996; Sheppard et al., 1995). For those who do develop genital warts,
reoccurrences of warts are common (Sheppard et al., 1995; Filiberti et al., 1993; Maw et al.,
1998; Voog et al., 1992) and treatment of warts with harsh chemicals and acids can be painful,
debilitating, and expensive.
There are severe mental health implications for contracting genital warts, in addition to
the earlier stated physical health risks. Patients with genital warts report greater psychological
distress, including anger, shame, isolation, depression, and guilt (Jeynes et al., 2009). Those with
genital wart symptoms report a lower Health Related Quality of Life (HRQoL) than those
without warts (Jeynes et al., 2009). Internalized shame and intrusive thoughts associated with
genital wart infection are strong predictors of poor HRQoL (Jeynes et al., 2009). Moreover,
shame associated with having an STI is associated with not seeking medical treatment among
adolescents (Fortenberry, 1997). As a result of not seeking medical treatment, young adolescents
may expose themselves to greater risks (e.g., contracting HIV or other STIs). There are
potentially severe health consequences for men who contract genital warts from HPV infection,
and the mental health consequences of having genital warts cannot be ignored.
Associated Risk Factors for HPV Infection in Men
There are differences between men who have sex with women (MSW) and MSM in
terms of HPV infection and cancer related outcomes (Johnson et al., 2004; Gilbert et al., 2011c;
Anderson et al., 2008; Pierangeli et al., 2008). MSM tend to have generally more positive
attitudes towards vaccinating against HPV with the Gardasil vaccine (Gilbert et al., 2011b). This
may be due to MSM being consistently at risk for STIs, and the Gardasil vaccine among MSM
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individuals tends to be evaluated more favorably in MSM than in MSW (Gilbert et al., 2011b).
Moreover, having anal sex with other men also predicts HPV infection (Lajous et al., 2005).
HPV is a virus that does not just exist internally, as studies have shown that the scrotum
and inguinal area can harbor large amounts of HPV (Dunne, Nielson, Stone, et al., 2006). This
adds to infection risk, as the virus can easily move to more habitable areas (e.g., the coronal
sulcus of the penis, or the anus). Circumcision is a protective factor in preventing later HPV
infection, as the virus can stay housed within the foreskin of the penis longer than those in
circumcised men, creating a longer persistence of the virus (Svare et al., 2002). HPV can survive
for long periods of time in the glans of the penis underneath the foreskin. Biological studies have
illustrated that men who are not circumcised are more likely to be infected with HPV than those
who are circumcised (Svare et al., 2002).
HPV type 16 is among the most aggressive and virulent strain in terms of cancer risk, and
past research has shown it to be most common in men (Dunne, Nielson, Stone, et al., 2006). In a
study by Lajous and colleagues (2005), 51.1% of men with HPV had more than one strain. This
suggests that men may be at a higher risk for certain HPV related cancerous outcomes, as
multiple HPV infections are associated with greater persistence of the virus (Kjaer et al., 2005;
Lajous et al., 2005).
HPV Attitudes, Willingness to Vaccinate, and Intentions to Vaccinate.
Evidence has shown that having a vaccine available does not necessarily lead to high
uptake in the population (Gonik, 2006; Zimet et al., 2000). Attitudes towards vaccination are a
likely reason for this, particularly as Gardasil has attracted a lot of attention on the Internet as a
potentially dangerous vaccine. Some barriers to receiving the Gardasil vaccine in men include
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the belief that men do not benefit from the Gardasil vaccine (Ferris et al., 2008) and that Gardasil
is too new to be trusted (Crosby et al., 2011).
Another challenge associated with encouraging HPV vaccination is that HPV infection is,
for the most part, invisible. HPV does cause genital warts, which are a very visible
manifestation, but this manifestation can easily be suppressed by the immune system, similar to a
herpes virus. Long-term outcomes of HPV include cancer, but unlike some other STIs, there are
very few immediate outcomes of HPV infection; even genital warts take as long as 6 months to
surface, and only occur in a small proportion of those infected with HPV (National Library of
Medicine, 2011; CDC, 2011a). As viral symptoms from HPV are essentially invisible for some
time, this could cause individuals who are infected to not attend to their infection. Research has
shown general support for this, as a lack of knowledge of, and familiarity with HPV predicts a
lower likelihood of vaccination (Bendik et al., 2011).
Sexual orientation. Research on MSM’s attitudes towards the HPV vaccine has shown
gay men to be more favorable to the Gardasil vaccine than are heterosexual men (Gilbert et al.,
2011b). Among MSM, those who are HIV positive are more favorable towards the Gardasil
vaccine, potentially because they are more health conscious, as HIV treatment adherence is
paramount for those infected (Gilbert et al., 2011b). Gay and bisexual identified men tend to
have more accurate knowledge of HPV related outcomes, as well as higher perceived likelihood
of contracting HPV (Gilbert et al., 2011b). MSM tend to have more severe HPV related
outcomes than do heterosexual men (Gilbert et al., 2011b), and are 17 times more likely to
develop anal cancer from HPV 16/18 infection than do MSW (CDC, 2011b).
While the differences between straight and gay men in terms of outcomes have been
demonstrated, HPV type 16 is among the most common HPV strain among both gay and
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heterosexual identified men (Nyitray, Carvalho da Silva et al., 2011). As HPV type 16 is the
most virulent cancer causing strain of HPV (Svare et al., 2002), it is important for prevention
work to address both gay and heterosexual identified men.
Cost. The findings are mixed as to how the cost of Gardasil is associated with intentions
to receive the Gardasil vaccine. While on one hand, cost is a factor that is consistently predictive
of willingness to vaccinate, acceptance of the HPV vaccine, and intentions to receive the vaccine
among men, gay men, and women (Simatherai et al., 2009; Allen et al., 2009; Gerend & Barley,
2009; Daley, Marhefka, Buhi et al., 2010; Burke, Vail-Smitch, et al., 2010; Young et al., 2010;
Rhodes & Arceo, 2004). On the other hand, cost may not be as consistent a barrier as it has been
reported in past research. In multivariate analyses, concerns about HPV vaccine cost seems to
disappear as a significant predictor of HPV intentions to vaccinate, and acceptability of the
vaccine (Hernandez et al., 2010; Crosby et al., 2011). This suggests that cost may be concomitant
with other predictors (e.g., having healthcare), and may not be an independent predictor of
receiving the vaccine when added to a multivariate analysis. In a study by Hernandez and
colleagues (2010), those who cited cost as a barrier to vaccination were more likely to intend to
vaccinate with Gardasil, and those who indicated that cost would be a major deciding factor in
HPV vaccination were more likely to intend to vaccinate as well. This could be due to the many
different cross-sectional samples utilized to study the effects of cost on HPV vaccine acceptance,
willingness, and intentions to vaccinate.
The retail cost of the HPV vaccine is $130 dollars per dose, for a total of $390 dollars for
the entire 3 shot series (CDC, 2011d). This cost is much higher than that of other vaccines, and
this potentially creates a greater barrier to vaccination for those without means to pay.
Considering this, men’s estimation of the personal amount they are willing to pay for the
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Gardasil vaccine is, on average, between $110 and $130. This could further illustrate that cost
may not be as great a barrier as it is reported to be. What is studied less is the perceived ability to
obtain the vaccination, which may be also be associated with perceived ability to pay.
The media. Straight identified men report a lower acceptance of the HPV vaccine than
do women (Gilbert et al., 2011). When compared to MSM, straight men have less positive
attitudes towards HPV vaccination. Another study showed that that having greater knowledge of
HPV and having heard of the vaccine was associated with a decreased willingness to receive the
vaccine (Daley et al., 2010). A potential reason for this is a lack of knowledge about HPV and
the Gardasil vaccine. The outreach programs by Merck & co. have urged women to be
vaccinated in their advertisements. The media may have a strong influence on health beliefs and
behaviors (Hay et al., 2009), and these advertisements may have influenced men to not see
themselves at risk. In fact, research on male HPV vaccine attitudes has shown this to be a
common belief. Men have reported in qualitative studies that they are not worried about HPV
(Allen et al., 2009), do not perceive themselves as at-risk for HPV infection (Allen et al., 2009),
and believe that the HPV vaccine does not benefit men (Crosby et al., 2011). Some research
shows that media can be used to improve male intentions to receive the Gardasil vaccine. For
example, a study by DiClemente and colleagues (2011) concluded that any form of HPV
prevention message given via a short PowerPoint presentation was enough to significantly
increase intentions to vaccinate with Gardasil among men.
There is a wealth of misinformation about vaccines on the Internet (Kata, 2010;
Zimmerman et al., 2005), including entire websites dedicated to “proving” that Gardasil causes
seizures, disability, and death in many of those who receive the vaccine (e.g.,
“TruthAboutGardasil.com”). These websites tend to use anecdotal evidence, logical fallacies,
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and scare tactics to suggest that Gardasil is not safe (Zimmerman et al., 2005). In spite of the low
harm rates associated with receiving the Gardasil vaccine, there is still mistrust of the Gardasil
vaccine and vaccinations in general on the Internet. The Internet represents a pathway for
individuals to gain information that may or may not be accurate, and vaccine information
gathered from the Internet may contain false information (Zimmerman et al., 2005). What is
most concerning about these claims is that they are typically untrue, as Gardasil is as safe as
other vaccines available (FDA, 2009). This information may in turn steer men away from
thinking they are at risk for HPV infection, that HPV is dangerous, and that men do not need to
be protected from HPV.
Moreover, television commercials by Merck & co. are targeted at educating women about
HPV infection, and encouraging early vaccination with Gardasil. These advertisements are
deliberately targeted at women. Some newer advertisements have begun to target men and boys,
but these advertisements may not be widespread enough to have the intended impact. Despite
CDC suggestions that men vaccinate against HPV along with women, there are few
advertisements targeted at a male audience. This may create a normative belief, suggesting to
men that they do not need the Gardasil vaccine, and potentially engender a belief that HPV is not
a concern for them. Despite clear research on the topic of media influence, there is very little
literature that seeks to identify how media influences both Gardasil vaccine attitudes, and
intentions to receive the Gardasil vaccine.
The media can also present images and discourse from political figures that may relate
inaccurate information on vaccination. For instance, on September 12, 2011 Republican
presidential hopeful Michele Bachmann publically proclaimed that Gardasil causes retardation,
based off an encounter with a mother who claimed that Gardasil caused her daughter to become
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mentally retarded. This comment sparked outrage from the American Academy of Pediatrics
(AAP), who insisted that the vaccine was safe (AAP, 2011). Statements like this from political
figures or media personalities may make individuals, including men, question the safety of the
Gardasil vaccine unnecessarily as they come into contact with inaccurate media sources.
Sexual behavior. As sexual behavior is the primary method by which individuals
contract HPV, past research has assessed how sexual activity influences attitudes towards the
HPV vaccine. Research generally shows positive relationships between sexual behavior and
HPV vaccine acceptance, willingness, and intentions to vaccinate. Being sexually active, having
multiple partners, and having oral sex are all associated with willingness to vaccinate with the
HPV vaccine, acceptance of the Gardasil vaccine (Gerend & Barley, 2009; Ferris et al., 2009;
Crosby et al., 2012). These findings can be explained in many ways. Men who have sex often
may be more informed about STI prevention, and may have more positive attitudes towards
Gardasil as a result. Frequent sexual activity may expose an individual to resources whereby
information about HPV is available. For instance, a sexually active individual may retrieve
condoms from free resources (e.g., medical clinics) and subsequently gain information about
Gardasil and HPV from resources available there.
One robust predictor of intent to vaccinate among men is ever having had oral-genital sex
(Crosby et al., 2011; Crosby et al., 2012). This finding is curious, as it seems that oral-genital sex
is associated with intent to vaccinate, over and above other sexual behavior predictors that might
seem more relevant (e.g., multiple penile-vaginal sex partners, having had sex with a male
partner, mutual masturbation, and unprotected penile-vaginal sex). There are a few reasons that
might explain this relationship. Oral sex tends to be more common than vaginal sex in young
samples (Halpern-Felsher et al., 2005; Malacad & Gretchen, 2010). More frequent oral sex might
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also create a heightened awareness about disease transmission, and subsequent perceived risk for
oral cancers (Crosby et al., 2012). This in turn may lead individuals to be more willing to take
any medical preventative measures to reduce any kind of infection (e.g., receiving the Gardasil
vaccine).
Medical provider influence. In numerous studies, willingness to receive Gardasil was
associated with a belief that a doctor would recommend the vaccine (Gilbert et al., 2011a;
Gilbert et al., 2011b; Daley et al., 2010). Medical providers can be a source of knowledge about
disease and health behaviors. Medical providers are authority figures that can dispel incorrect
information learned from media sources. In fact, the field of health psychology has examined
patient-provider interactions in terms of health behaviors (Barlett et al., 1984; Becker, 1985),
strengthening the notion that medical providers can cause behavior change.
Medical attendance can be a gendered event, as women tend to take a more active role in
their medical decisions (Arora & McHorney, 2000), and women tend to receive more medical
information than men (Waitzkin, 1985). Women often receive routine pap tests, whereas men
have no comparable routine examination that could potentially detect HPV related cancers in
their early stages. Pap tests have a clear HPV-related focus and patients may potentially dialogue
with their medical provider about the vaccine. Among women, a provider recommendation for
vaccination is significantly associated with being vaccinated against HPV, with a stronger
recommendation being more likely to increase vaccination than a weaker recommendation
(Rosenthal et al., 2011).
Racial differences. The literature on racial differences in HPV vaccine acceptance,
willingness, and intentions to vaccinate is mixed. Many studies that have controlled for race have
found significant effects over and above race. However, studies have also shown significant
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differences between races in vaccine acceptance and willingness to receive the Gardasil vaccine
(Ferris et al., 2009). A study by Ferris and colleagues (2009) demonstrated that white men were
generally more undecided about receiving the HPV vaccine, and when compared to White men,
Black men were more willing to receive the HPV vaccine.
Racial differences in intentions to receive the Gardasil vaccine may attenuate in
multivariate statistical analyses. Many studies on racial differences illustrates that race may not
be an influential factor in intentions to receive the Gardasil vaccine. For example, Daley and
colleagues (2010) found that race was not a significant predictor of intentions to receive the
Gardasil vaccine, while Hernandez and colleagues (2010) found no racial differences in
awareness, attitudes, and intent to vaccinate with the HPV vaccine.
One potential criticism of these research studies is that they have utilized largely white
samples. All articles cited had a majority of white identified individuals as participants.
Furthermore, these studies may be influenced by time of data collection. Variability in any type
of HPV vaccine related questions could be constricted, as the HPV vaccine has only been
available since 2006. A lack of racial diversity in the samples may be a crucial variable that may
mask true racial differences in intentions to receive the HPV vaccine.
Use of Theoretical Frameworks in HPV Research
Past research has attempted to utilize portions of theoretical models to predict Gardasil
acceptance, willingness, and intentions to initiate Gardasil vaccination. These studies mainly
look at variables that are a part of the health belief model (HBM), but further provide theoretical
justification for use of other theory.
The Health Belief Model
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The HBM suggests that the likelihood of an individual participating in an action
necessary to avoid a disease is dependent on the perceived susceptibility to the disease, the
perceived severity of the disease, the perceived benefits of engaging in a behavior that will
prevent a disease, the perceived barriers to engaging in that behavior, and “cues to action” which
refer to influences, either inside or outside, oneself that encourage one to engage in a behavior
(e.g., breaking out with acne would be a cue to action to engage in face washing behavior).
Past studies have shown some support for parts of the health belief model in predicting
intentions to vaccinate with HPV vaccine. In a study of parental intentions to vaccinate their
children, parent’s perceived benefits of vaccination and perceived susceptibility of their child
contracting HPV were significant predictors of intentions to vaccinate their male child (Dempsey
et al., 2006). Among adult men, perceived susceptibility to HPV was associated with willingness
to receive the HPV vaccine, and willingness of parents to vaccinate their child (Crosby et al.,
2011; Dempsey et al., 2006; Dempsey et al., 2011), as well as in other studies that predicted
feelings towards receiving the HPV vaccine (Boehner et al., 2003; Friedman and Shepeard,
2006). Specifically in a study by Dempsey and colleagues (2011), all arms of the HBM were
predictive of parental intent to vaccinate their young, adolescent male children, except for
perceived severity (cues to action were unmeasured). Perceived barriers such as cost and vaccine
safety (discussed earlier) may not be the best predictors of Gardasil vaccine acceptability in men.
In a recent study of women, Gerend & Shepherd (2012) found that perceived severity in itself
was not a significant predictor of receiving the HPV vaccine. Moreover, perceived severity has
not been associated with vaccine acceptability in other studies of samples with men and women
examining an array of vaccination behaviors (Boehner et al., 2003; Dempsey et al., 2006; Kahn,
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Rosenthal, Hamann, & Bernstein, 2003). A caveat to this research is that these studies examined
acceptability, and not likelihood, willingness, or intentions to receive the HPV vaccine.
Perceived severity of HPV has also been a poor predictor of acceptability of the Gardasil
vaccine in studies comparing gay and bisexual men against heterosexual men. HIV negative men
have no relationship between perceived severity and Gardasil acceptability, while HIV positive
men with higher perceived severity have greater acceptability of the Gardasil vaccine (Gilbert et
al., 2011a). An interesting factor in male Gardasil acceptance and perhaps intentions to receive
the vaccine seems to be HIV status. Gilbert and colleagues (2011b) found that HIV infected gay
men had a strong positive relationship between perceived severity of HPV and intentions to
vaccinate, while HIV-negative gay men had no relation between perceived severity and
intentions. This could illustrate that individuals with chronic illness may be more sensitive to
preventative health measures.
The HBM has historically done a poor job of predicting the likelihood of receiving the
Gardasil vaccine. In many studies, HBM factors like perceived severity of HPV infection were
not predictive of acceptability of the HPV vaccine (DiAngi, Panozzo, Ramogola-Masire,
Steenhoff, & Brewer, 2011; Boehner et al., 2003; Dempsey et al., 2006; Kahn et al., 2003).
Many studies do not use theoretical frameworks to study Gardasil vaccine initiation, and of those
studies that do, they sample mostly women. Furthermore, the use of the HBM has often been
studied with parents’ intentions to vaccinate their children. This leaves adults relatively ignored
in the literature that attempts to use theory as a framework to predict intentions to receive the
HPV vaccine. Instead of using the HBM as a model for predicting health behavior engagement,
the Theory of Planned Behavior (TPB) may provide a more accurate framework for predicting
health behaviors, such as receiving the Gardasil vaccine.
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The Theory of Planned Behavior
The TPB posits that the strongest predictor of any given behavior is the intention to
engage in that behavior (Ajzen, 1991). The TPB model posits that attitudes towards the behavior,
perceived normativity of that behavior, and one’s ability to control their engagement in that
behavior (perceived behavioral control) are the most proximal predictors of intentions (Ajzen,
1991). Attitudes in the TPB consist of two constructs: behavioral beliefs, and attitudes towards
the behavior. Behavioral beliefs refer to the perceived consequences of engaging in a particular
behavior, while attitudes towards the behavioral refer to the evaluation of the behavior as
positive or negative. A recent comparison of the HBM and the TPB has given strong evidence
for the TPB as the better model for predicting vaccine uptake among young adult women
(Gerend & Shepherd, 2012). As such, the TPB may perform best as a model for predicting HPV
vaccine intentions in men as well. Furthermore, TPB has also been successful in predicting many
different health behaviors (e.g., Armitage & Conner, 2001; Bogart & Delhanty, 2004).
Perceived norms. Perceived norms represent the perception of important others’ beliefs
regarding a behavior (Ajzen, 1991). Moreover, perceived norms also include a reflection on how
relevant one perceives those beliefs of important others’ to be. Past research has illustrated some
of the ways in which norms can influence the willingness to receive the HPV vaccine. For
example, a study by Reiter and colleagues (2011), young boys were more willing to receive the
HPV vaccine if they perceived that their peers would accept them for it, if they would later regret
not getting the vaccine, and perceived themselves to be vulnerable to getting HPV; of these
predictors, perceived peer acceptance was the strongest. There are more promising predictors of
willingness to receive the Gardasil vaccine that are associated with parental attitudes. Among
minor young adults, parental attitudes tend to be strongly associated with male child attitudes
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towards HPV (Reiter et al., 2011). In fact, recommendations from powerful others (e.g., parents,
doctors) tend to be strong predictors of acceptance of the Gardasil vaccine (Ferris et al., 2008,
2009; Boehner et al., 2003; Hollander, 2010).
Attitudes. Attitudes in the TPB model consist of two constructs: Behavioral beliefs and
attitudes towards the behavior. Behavioral beliefs refer to the believed consequences for
engaging in a particular behavior. Attitudes towards the behavior refer to the evaluation of the
behavior as positive or negative. Together, these two constructs represent the attitudes variable in
the TPB model.
Parental attitudes towards HPV have been correlated with willingness to receive the
Gardasil vaccine in young male children. A study by Reiter and colleagues (2011) measured the
predictors of parent intention to vaccinate their male child (ages 11-17) with an HPV vaccine, as
well as child intention to receive an HPV vaccine. Results showed that numerous different
attitudes (e.g., harmfulness of the vaccine) towards the HPV vaccine were significant, predictors
of intentions to vaccinate their child. Uncertainty about the HPV vaccine seems to be readily
apparent in all research reports that examine it. A qualitative investigation by Allen and
colleagues (2009) reported that the men in their sample reported apprehension towards Gardasil
based on reported fears of side effects and safety of the vaccine. One participant even stated that
“there’s been so many things that women have taken that have supposed to help them which
have ended up being negative for them” (Allen et al., 2009, p.536). These beliefs that Gardasil is
unsafe, in turn, have been shown to predict, in general, negative attitudes towards receiving the
HPV vaccine (Ferris et al., 2009; Boehner et al., 2003). These predictors also tend to be very
robust. A study by Crosby and colleagues found that believing that the HPV vaccine was too
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new to receive was one of three remaining significant predictors of intent to vaccinate with
Gardasil when entered into a multivariate model along with many other variables.
The items created by (Reiter et al., 2011) for the purposes of their research contained
questions that tapped into attitudes towards Gardasil vaccination, but have mainly been used for
parental attitudes towards vaccinating one’s child (Reiter et al., 2011). These attitudinal factors
tend to be predictive of receiving the Gardasil vaccine. Past research has taken portions of
attitudinal beliefs (as defined by the TPB) to predict HPV vaccine acceptance and intention to
initiate vaccination, but attitudinal variables tend to be poor predictors of a behavior alone
(Fishbein & Ajzen, 1974). Little research has specifically looked at attitudes towards HPV and
Gardasil among adult men.
Perceived behavioral control. Perceived Behavioral Control (PBC) is the most robust
predictor in the TPB. This construct represents the perceived ease at which an individual believes
they can engage in a particular behavior. PBC theoretically predicts intentions to engage in a
behavior, as well as directly predicts the behavior itself (Ajzen, 2002). Much research has used
measures of self-efficacy to describe PBC, but Ajzen (2002) objects by stating that PBC
conceptually represents both perceived self-efficacy, and perceived controllability. For efficacy
to be truly predictive of a behavior, an individual must not only believe he or she can engage that
behavior (self-efficacy), but also feel that they have control over their ability to engage in that
behavior (perceived controllability). Furthermore, Terry & O’Leary (1995) illustrated that
perceived controllability and perceived self-efficacy were two separate parts of PBC, and have
better predictability separately than together. Ajzen (2002) concludes that PBC is better
conceived as a factor that makes up two latent constructs: perceived self-efficacy and perceived
controllability.
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No study to date has examined PBC in relation to receiving the Gardasil vaccine, but a
few studies have included measures that shed light on its predictive power. A study by Crosby
and colleagues (2011) found that self-efficacy to be vaccinated with Gardasil is not predictive of
intentions to receive the vaccine. A study by Hernandez and colleagues (2010) included a
variable in their analysis of vaccination intentions that asked whether transportation to a clinic to
receive the vaccine would influence vaccination intentions; this was not significant in their final
analysis. The studies suggest that PBC-related variables may not factor into intentions to receive
the Gardasil vaccine.
While past studies may not support PBC in predicting HPV vaccination, the context of
the research on Gardasil and the HPV vaccine must be taken into account when critically
analyzing the results of past research. Gardasil was not approved for male use until years after
the vaccine was introduced, and the vaccine is still relatively new. Older studies, and even
currently published ones, use data from around or before the time when Gardasil was approved
for male use. It is plausible that PBC may not have been a relevant predictor of intentions to
receive the HPV vaccine because participants may never had heard of it, or they did not believe
it is for them. In fact, Crosby and colleagues (2011) also found that belief that one should wait to
be vaccinated because the Gardasil vaccine is too new was a significant predictor of not
intending to receive the Gardasil vaccine. The key fact that must be considered for future
research is that the more recent studies, with newer data, will provide the most useful
information on intentions to receive Gardasil, as the vaccine becomes more normative and the
risks associated become better understood by the lay population.
As many studies use the health belief model as a partial framework, but do not complete
the model by including all relevant predictors. This is a common criticism of the literature that
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utilizes the health belief model (Bogart & Delahanty, 2004). Psychosocial theories on health
behaviors are helpful for predicting whether or not individuals participate in certain health
behaviors, including receiving the Gardasil vaccine. While these studies present interesting
associations of willingness to receive the HPV vaccine, the TPB provides a standard framework
that predicts intentions to engage in health behaviors (Ajzen, 1991), and can be applied to
intentions to receive the vaccine. A major benefit of using the TPB is its history of being used in
successful studies, many of which include sexual topics like condom usage (Bogart & Delhanty,
2004).
The Present Study
The purpose of the study is to examine intentions to receive the HPV vaccine among
men. The present study will seek to use the TPB to model intentions to receive the HPV vaccine
among young adult males. The HPV vaccine, Gardasil, has only been available since 2006, and
most of the research currently published was done with data collected very near, or even before,
the time when the vaccine became available. As such, with the majority of the HPV research
literature focusing on women and their subsequent HPV risk, attitudes, and willingness to
receive the Gardasil vaccine, additional research is warranted to address men as well.
Hypothesis 1: Males will have adequate variability in their intentions to receive the
Gardasil vaccine. Past research that has evaluated males intentions has found adequate variability
in questions that measure HPV vaccination intentions, willingness, and acceptance (e.g., Reiter
et al., 2011; Daley et al., 2011; Daley et al., 2010). Daley and colleagues (2011) reported high
intentions in to receive the Gardasil vaccine in the next 6 months (greater than 70% of the
participants rated themselves as at least likely to receive the vaccine). Evaluating the skewness
and kurtosis values for the intentions variable will statistically test this hypothesis. These
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skewness and kurtosis values are hypothesized to be less than |1.5|. If the values are greater than
this, the score will be dichotomized so that the intentions variable represents those who intend to
receive the HPV vaccine in 6 months, and those who do not intend to receive the HPV vaccine in
3 months.
Hypothesis 2: As race has been inconsistently associated with intentions to receive the
HPV vaccine, a one-way ANOVA will be performed to evaluate racial differences in intentions
to receive the Gardasil vaccine. Bonferonni post hoc tests will evaluate main effects of racial
differences. It is hypothesized that non-white individuals will have greater intentions to receive
Gardasil.
Hypothesis 3: As intentions to receive the Gardasil vaccine have been shown to be
different as a function of sexual orientation, a one-way ANOVA will be performed to evaluate
differences in intentions to receive the vaccine among gay, bisexual, straight, and queer
identified adults. It is anticipated that non-heterosexual identified participants will report greater
intentions to receive the Gardasil vaccine.
Hypothesis 4: Past research suggests that individuals who have greater sexual partners
report greater willingness to receive the Gardasil vaccine, as well as acceptance of the vaccine
(Gerend et al., 2008; Jones & Cook, 2008; Ferris et al., 2009). As such, it is hypothesized that a
spearmans rho correlation will reveal a significant positive correlation between number of sexual
partners in the past 3 months and intentions to receive the Gardasil vaccine.
Hypothesis 5: As DiClemente and colleagues (2011) illustrate, something as simple as a
commercial can increase intentions to receive the Gardasil vaccine among men. As such, it is
hypothesized that those with who are highly influenced by Gardasil commercials will have
significantly lower intentions to receive the Gardasil vaccine.
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Hypothesis 6: Attitudes towards HPV vaccination, perceived norms associated with HPV
vaccination, and perceived behavioral control will all independently predict intentions to be
vaccinated against HPV with the Gardasil vaccine. Furthermore, the TPB model will fit the data
well, with a Root Mean Squared Error of Approximation (RMSEA) less than .05. The chi-square
value for the overall model will not be significant, indicating that there is not a significant
amount of unexplained variance in the model. The model will control for racial demographics,
sexual orientation, and sexual behavior, as these factors have been associated with willingness to
receive the Gardasil vaccine.
The postulated direction of relationships is as follows: those with more positive attitudes
towards Gardasil will report greater intentions to receive the Gardasil vaccine. Those with more
positive perceived norms will report greater intentions to receive the Gardasil vaccine. Those
with greater perceived behavioral control will report greater intentions to receive the Gardasil
vaccine.
Method
Procedure
Power analysis illustrated that with 10 predictors in the model, an n = 155 participants
were sufficient to detect a small effect at .80 (80%). Participants were undergraduate psychology
students who completed a survey online. Participants were given course credit for their
involvement in this project. Participants were asked if they would like to complete a survey on
sexually transmitted disease attitudes. Before participants began the survey, they completed an
electronic informed consent that detailed that participation is voluntary and they could refuse to
answer any questions that they are not comfortable answering. Only those who identified as male
and between the ages of 18-26 were asked to participate. The present study was completely
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anonymous and approved by the Institution Review Board (IRB) at Virginia Commonwealth
University (VCU).
Materials
Demographics. Participants were asked about their gender, sexual orientation, ethnicity,
age, and relationship status. Gender was asked to ensure that only male identified participants are
participating. The main purpose of asking about age was to ensure that participants fell between
the ages of 18 and 26.
Attitudes Towards HPV Vaccine. Attitudes towards HPV were measured using the
“harms” subscales of the Carolina HPV Immunization Attitudes and Beliefs Scale (CHIAS;
McRee et al., 2010). This subscale measured HPV attitudes and beliefs. The “harms” subscale
contains 6 items (α = .69) and measures the degree to which individuals perceive the HPV
vaccine to be harmful (e.g., “The HPV vaccine might cause lasting health problems.”).
Responses ranged from 1 (Strongly Agree) to 4 (Strongly Disagree). In addition to these items,
the present study utilized additional items to further examine the construct of attitudes, by using
items borrowed from a sample TPB questionnaire (Ajzen, 2012), these items had responses
ranging from 1 (Strongly Agree) to 4 (Strongly Disagree). These questions measured general
attitudes towards the HPV vaccine. These measures will together estimate the construct of
“Attitudes towards receiving the HPV vaccine”. Higher scores on these measures will represent
more positive attitudes towards the HPV vaccine. Relevant items were reverse coded.
Perceived norms. Perceived norms were measured with an aggregate of theoretically
oriented items from a sample TPB questionnaire (Ajzen, 2012). An example of one of these
items is “My parent would think it would be a good idea for me to receive the Gardasil vaccine.”
Responses ranged from 1 (Strongly Agree) to 4 (Strongly Disagree). As perceived norms also

29

contain an evaluative component, participants were asked questions that measure how they
evaluate their norms (e.g., “How much do you value your friends’ opinions in your decision to
get the Gardasil vaccine?“). Responses ranged from 1 (Very Little) to 5 (Very Much).
Perceived behavioral control. The “barriers” subscale of the CHIAS was combined with
3 theoretically relevant items from Azjen’s TPB sample survey (Ajzen, 2012) to measure
perceived behavioral control. This subscale contains 5 items (α = .69), plus 3 from Ajzen’s
sample survey for a total of 8 items, and measures perceived ability to receive the HPV vaccine
(e.g., “I am concerned that the HPV vaccine costs more than I can pay”), responses ranged from
1 (Strongly Disagree) to 6 (Strongly Agree) or 1 (Not difficult at all) to 6 (Extremely Difficult)
where appropriate. Control beliefs were measured also (e.g., “Unanticipated events would make
it unlikely for me to receive the Gardasil vaccine”), responses ranged from 1 (Strongly Disagree)
to 5 (Strongly Agree). Together, these two constructs together represent the latent construct of
“Perceived behavioral control towards receiving the HPV vaccine”. For perceived self-efficacy,
higher scores represent greater efficacy towards receiving the HPV vaccine. For perceived
controllability, higher scores represent less controllability towards receiving the HPV vaccine.
Sexual behavior. Participants were asked to report the number of sexual partners that
they had in the past 3 months. Research has demonstrated that individuals who are sexually
active are more willing to receive the Gardasil vaccine (Gerend et al., 2008; Jones & Cook,
2008; Ferris et al., 2009; Crosby et al., 2012).
Media influence. Participants were asked two types of questions, the first type measured
media influence from the HPV vaccine commercials, such as “Seeing the Gardasil commercials
on TV make me feel like I shouldn’t get the vaccine.”. The second type of question measured
general use of media for health information, by asking questions such as “How often do you use
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the Internet/Radio/Television for health information?”. Similar questions have been used in past
research (Ben-Zur et al., 2012). Responses ranged from 1 (Strongly Disagree) to 5 (Strongly
Agree) and 1 (Not at all often) to 5 (Very often) for each question where appropriate. Each item
included the option to opt out due to non-exposure (e.g., “N/A, I have not seen a Gardasil
commercial.”). Higher scores on this measure indicate greater influence from the media when
deciding to vaccinate with the HPV vaccine.
HPV vaccination intention. Behavioral intention was measured with a single item
“There is a vaccine available that can protect you against HPV (e.g., Gardasil), to what degree do
you intend to receive this vaccine within the next 6 months?” Responses ranged from 1 (Not at
all likely) to 4 (Very likely). Items similar to this have been used in past research (e.g., Daley et
al., 2011). Higher scores on this item represent greater intention to receive the HPV vaccine.
Data Analysis
As the present research used measures constructed for the purposes of this specific study,
factor analysis was performed on all scales used in this study. Reliabilities were also checked for
each sub-factor, and items that load onto both factors will be deleted so as to have a goal
Cronbach’s alpha above .70.
One-way ANOVAs were performed to test differences in sexual orientation as well as
racial differences in intentions to receive the HPV vaccine. Tukey post-hoc tests were performed
to confirm significant mean differences between these groups.
Spearman’s rho correlation tested the hypothesis that greater sexual frequency (defined as
the number of sexual partners in the past 3 months) will be associated with greater intentions to
receive the HPV vaccine. It is expected that those with greater sexual frequency will report
greater intentions to receive the HPV vaccine.

31

Pearson’s r correlations were performed to examine the relationship between media
influence and intentions to vaccinate.
The TPB posits that normative beliefs, attitudes towards the behavior, and perceived
behavioral control will predict behavioral intentions (Azjen, 1991). Figure 1 illustrates the
hypothesized structural equation model of vaccination intentions. This model was tested using
AMOS software version 20.

Figure 1. Proposed structural equation model to test the theory of planned behavior.
Data Quality Assurance
Participants who reported already having received the HPV vaccine were eliminated (n =
41), leaving a final sample size of n = 226. As sample size was small, and many parameters are
being estimated, a Bollen-Stine bootstrap was performed to correct for small sample size (n =
500 samples). Reliability analyses (Cronbach’s α) and exploratory factor analyses were
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performed to eliminate potentially poorly worded or poor fitting items to the respective
constructs being measured. An additional benefit of these procedures was to ensure adequate
power, and to further reduce the amount of parameters estimated given the relatively small
sample size (n = 226). There were no missing values in the present dataset, so the full sample
size of 226 was retained throughout the analysis. Analyses were performed with AMOS version
20 and SPSS version 20.
Results
The sample consisted of 50.6% White identified individuals, 18.3% African-American,
7.2% Hispanic/Latino, 17.4% Asian American, and 6.4% identified as “Other”. Average age was
19.23 (SD = 1.78). Most of the sample consisted of students in their freshman year of college
(62.1%), with 19.1% identifying as sophomore, 12.3% as Junior, 6.0% as Senior, and .4% (n = 1)
as in their 5th year. Most of the sample (92%) identified as heterosexual, with 1.8% identified as
bisexual, and 6.2% identifying as gay/homosexual.
Hypothesis 1
Normality of the vaccination intentions item was examined using skewness and kurtosis
statistics. As a general rule of thumb, skewness and kurtosis less than |1| suggest a normal
distribution. Results indicate that the HPV vaccination intention item was normally distributed
(Skewness = .052, SE = .16), (Kurtosis = -.638, SE = .32), M = 2.42, SD = .86; Range: 1 – 4.
Hypothesis 2
The second hypothesis was to evaluate racial differences in the intentions variable. A
one-way ANOVA as performed on the intentions to receive the HPV vaccine variable, which
indicated significant variability as a function of race F(4, 221) = 4.45, p = .002. Tukey post-hoc
tests indicated that the only significant racial difference was that between Whites (M = 2.27, SD
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= .87) and those who identified themselves in the “Other” category (M = 3.0, SD = .56), p = .02.
This indicates that those who identified as “Other” in their racial category had significantly
greater intentions to receive the HPV vaccine than did Whites. All other racial comparisons were
performed, and were not significant (p’s > .05; Figure 2).

Figure 2. Means of HPV vaccination intention among different races.
Hypothesis 3
The third hypothesis examined how sexuality was associated with HPV vaccination
intentions. A one-way ANOVA was performed to examine differences in HPV vaccination
intentions among those who identified as straight (heterosexual; n = 208), bisexual (n = 4), gay
(Homosexual; n = 14). Results indicated that there was no effect of sexuality on HPV
vaccination intentions F(2, 223) = 0.85, p = .43. The simple means for gay (M = 2.42, SD = .86)
and bisexual men (M = 2.75, SD = .86) were slightly higher than that of heterosexual men (M =
2.39, SD = .87), but not outside the range of sampling error. See Figure 2 for a visual
representation of the means.
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Due to this small sample sizes per cell for sexual orientation, Cohen’s d effect sizes for
the mean differences were computed. Cohen’s guidelines suggest that a value of .2 is small, .5 is
moderate, and .8 is large in effect. The difference between gay and heterosexual men yielded a
Cohen’s d value of .04, and the difference between heterosexual and bisexual men yielded a
Cohen’s d value of .42. This suggests that the mean differences between heterosexual and
bisexual men indicated a small effect, while the differences between heterosexual and
homosexual men had effects that did not even reach the threshold of “small” (.2). As only 4 total
participants identified as bisexual, a dummy variable was created to compare heterosexual vs.
non-heterosexual individuals in their intentions to receive the HPV vaccine. Results indicate no
statistically significant difference in vaccination intentions, t(224) = -1.29, p = .20, d = .34, but a
small effect size of the mean differences between the two groups.

Figure 3. Means of HPV vaccination intentions among different sexual orientations.
Hypothesis 4
The fourth hypothesis was to examine the relationship between number of sexual partners
and intentions to receive the HPV vaccine. Results suggest that there is no relationship between
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the number of sex partners in the past 3 months and intentions to receive the HPV vaccine
rs(223) = -.06, p = .36.
Hypothesis 5
The fifth hypothesis examined the impact of media influence on HPV vaccination
intentions. Given that a “NA” option was added to each question, a total of n = 117 people were
deleted from analysis for answering “no” to any question. This left a total of 118 participants to
analyze responses for media influence. An exploratory factor analysis was performed using
principal components analysis as an extraction technique and varimax rotation as a rotation
technique. Results indicated two factors that were indicated a priori. The first factor was media
influence [eigenvalue = 3.89, R2 = 35.35, α = .88] and, the second factor was use of the media for
health information [eigenvalue = 1.92, R2 = 17.41, α = .62], see Table 1 for factor loadings. As
all items clearly loaded onto their respective factor, no items were deleted. Simple correlations
revealed that media influence was not associated with HPV vaccination intentions in men r(116)
= .15, p = .10. There was also no significant relationship between use of media for information
and HPV vaccination intentions r(116) = .02, p = .86. As there was no relationship between
media influence and vaccination intentions, the decision was made to use the full sample size of
226 for the test of hypothesis 6.

Table 1.
Factor loadings for the media influence items
Factor
Media Influence Items.
loading

Factor
loading
36

Mean (SD)

(Factor 1) (Factor 2)
1. Seeing the Gardasil
commercials on TV make me feel
like I shouldn’t get the vaccine.

.886

-.070

4.11 (1.68)

2. Seeing the Gardasil
advertisements in magazines
make me feel like I shouldn’t get
the vaccine.

.921

-.092

4.34 (1.68)

3. Seeing the Gardasil
advertisements in other print
media makes me feel like I
shouldn’t get the vaccine.

.918

-.077

4.31 (1.70)

4. I feel like HPV is not a concern
for me because of the Gardasil
commercials on TV.

.918

-.036

4.09 (1.72)

5. The information that I learned
about Gardasil on the Internet
makes me not want to get the
vaccine.

.896

-.102

4.25 (1.72)

6. The information that I learned
about Gardasil on the news makes
me not want to get the vaccine.

.911

-.133

4.22 (1.76)

7. I value what the Gardasil
commercials on TV have to say.

.849

.007

4.04 (1.75)

8. The Gardasil commercials on
TV are very informative to me.

.839

.023

3.99 (1.76)

9. How often do you use the
Internet for health information?

.055

.607

2.89 (1.26)

10. How often do you use the
-.023
Television for health information?

.895

1.87 (1.00)

11. How often do you use the
Radio for health information?

.747

1.50 (0.87)

-.226

Hypothesis 6: Theory of Planned Behavior Model for Predicting HPV Vaccination
Exploratory Factor Analysis
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To estimate the latent constructs in the structural equation model, indicators were created
from the scale items presented in the methods section. Exploratory factor analyses were
performed on all scales in this study to eliminate flawed items. Principal components analysis
was utilized as an extraction technique, and varimax rotation was performed as a rotation
technique. The decision was made to retain items with factor loadings above .60.
The attitudes towards vaccination measured loaded onto a single factor [eigenvalue =
3.70, R2 = .62; α = .87]; as such, all 6 items were retained in estimating the latent construct of
attitudes towards HPV vaccination (Table 2).
Table 2.
Factor loadings for the attitudes towards HPV vaccine items.
Attitudes towards HPV vaccine items.

Factor
loading

Mean (SD)

1. The HPV vaccine might cause short-term problems,
like fever or discomfort.

.753

3.80 (1.21)

2. The HPV vaccine is being pushed to make money for
drug companies.

.832

3.48 (1.49)

3. The HPV vaccine might cause lasting health
problems.

.825

3.77 (1.36)

4. If a teenage girl gets the HPV vaccine, she may be
more likely to have sex.

.774

3.28 (1.58)

5 I think the HPV vaccine is unsafe.

.787

3.53 (1.54)

6. Adolescent girls are too young to get a vaccine for
sexually transmitted infections, like HPV.

.737

2.90 (1.58)

The behavioral beliefs measure was submitted to factor analysis and revealed that 1 item
loaded onto a separate factor; this item was subsequently removed from analysis, leaving a 4-
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item measure of behavioral beliefs [eigenvalue = 2.65, R2 = .53; α = .80]. See Table 3 for the
factor loadings of these items. A strikethrough indicates that that respective item was deleted.
Table 3.
Factor loadings for the behavioral beliefs items
Behavioral Beliefs Items.

Factor loading
(Factor 1)

Factor loading
(Factor 2)

Mean (SD)

1. The Gardasil vaccine would be a good
health decision on my part.

.775

.180

3.26 (0.88)

2. Getting the Gardasil vaccine would
protect my future sex partners from HPV.

.798

.037

3.37 (0.98)

3. Getting the Gardasil vaccine would
help me to learn more about sexually
transmitted infections.

.734

.128

3.26 (0.96)

4. The Gardasil vaccine would make me
feel uncomfortable.

.155

.984

3.16 (1.01)

5. Getting the Gardasil vaccine would
help me to be healthier.

.808

.174

3.20 (0.90)

An identical factor analysis was performed on the perceived norms items, which loaded
onto three factors with an eigenvalue ≥ 1. The second and third factors had multiple items crossloading onto one another, suggesting that these items may be potentially poorly worded or
uncorrelated with other items in the scale; those items were removed from analysis. This resulted
in a 4-item measure that clearly loaded onto one factor to estimate the latent construct of
perceived norms [eigenvalue = 2.89, R2= .72; α = .87] Table 4 indicates the factor loadings for
the norms measure.

Table 4.
Factor loadings for the perceived norms items.
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Perceived Norms Items.

Factor loading Factor loading Factor loading Mean (SD)
(Factor 1)
(Factor 2)
(Factor 3)

1. My mother would
think it would be a good
idea to receive the
Gardasil vaccine.

.888

.006

-.004

3.16 (0.98)

2. My father would think .857
it would be a good idea
to receive the Gardasil
vaccine.

-.087

.120

3.14 (0.91)

3. My parent would
think it would be a good
idea to receive the
Gardasil vaccine.

.891

-.132

.090

3.19 (0.91)

4. I think my friends
would support my
getting the Gardasil
vaccine.

.557

-.482

.143

3.20 (0.85)

5. I think that Gardasil is
just for girls. In general,
I think that the people of
Virginia would not
support me getting the
Gardasil vaccine.

-.030

.848

.011

2.77 (0.90)

6. People who are
important to me would
not support me in
getting the Gardasil
vaccine.

-.558

.542

.204

2.62 (0.92)

7. I know other men
who have received the
Gardasil vaccine.

.019

.312

.815

2.26 (1.01)

8. The people whose
opinions I value most
would think it is a good
idea for me to get the
Gardasil vaccine

.613

-.363

.269

3.07 (0.95)

9. I value what the
.185
Gardasil commercials on

-.364

.763

2.78 (0.86)
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television tell me.

The 3-item measure for motivations to comply with norms were next entered into a
factor analysis, and the 3 items clearly loaded onto the one factor. As such, all 3 items were
retained to estimate motivations to comply with norms [eigenvalue = 2.46, R2 = .49; α = .85]
Table 5 shows the factor loadings and items for this measure.
Table 5.
Factor loadings for the motivations to comply with norms items.
Motivations to comply with norms items.

Factor loading Factor loading Mean (SD)
(Factor 1)
(Factor 2)

1. How much do you value your parents'
opinion in your decision to get the
Gardasil vaccine?

.880

-.032

2.93 (1.41)

2. How much do you value your friends’
opinion in your decision to get the
Gardasil vaccine?

.912

-.026

3.18 (1.34)

3. How much do you value the internet’s
opinion in your decision to get the
Gardasil vaccine?

.829

.254

2.75 (1.23)

The final factor analysis examined the measure of perceived behavioral control. Dimension
reduction revealed that 2 items loaded onto a second factor, and those items were subsequently
removed from analysis, leaving 6 items (Table 6) to estimate the latent construct of perceived
behavioral control [eigenvalue = 2.68, R2 = .54; α = .78].
Table 6.
Factor loadings for the perceived behavioral control items.
Perceived Behavioral Control

Factor loading Factor loading Mean (SD)
(Factor 1)
(Factor 2)
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1. Getting the Gardasil vaccine
would be easy for me.

.718

.232

3.21 (0.93)

2. It would be a good idea to get the
Gardasil vaccine.

.622

.364

3.14 (0.85)

3. Whether or not I get the Gardasil
vaccine is completely up to me.

.704

-.149

3.93 (1.13)

4. If I really wanted to, I know I
could get the Gardasil vaccine.

.744

.129

3.63 (1.05)

5. It is expected that I get the
Gardasil vaccine.

.078

.784

2.47 (0.93)

6. I will make an effort to get the
Gardasil vaccine

.031

.808

2.67 (0.95)

7. It would be difficult for me to get
the Gardasil vaccine.

.631

-.213

2.43 (0.93)

8. I am confident I can find a place
to receive the Gardasil vaccine.

.804

.148

3.53 (1.02)

Control beliefs loaded onto one factor [eigenvalue = 1.63, R2 = .54; Table 7], but did not
have adequate Cronbach’s alpha values (α = .58), and were removed from further analysis. Even
though control beliefs (which are theoretically part of the construct of perceived behavioral
control) were not adequately measured in this study, it is worth noting that many tests of the TPB
often substitute self-efficacy for perceived behavioral control (Gerend & Shepherd, 2012).
Table 7.
Factor loadings for the perceived controllability items.
Perceived Controllability

Factor
loading

Mean (SD)

1. Unanticipated events would make it unlikely for me
to get the Gardasil vaccine.

.634

2.94 (0.91)

2. If I didn’t feel well, I would make it more difficult to
get the Gardasil vaccine.

.785

3.08 (0.89)
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3. If my job or coursework put too many demands on
my time, it would make it difficult for me to get the
Gardasil vaccine.

.785

3.15 (0.96)

The means and standard deviations for all final scales are shown in Table 8.
Table 8.
Means and standard deviations of all constructs measured.
Construct

Mean (SD)

Media Beliefs

39.61 (12.23)

Attitudes Towards HPV

20.75 (6.88)

Behavioral Beliefs

10.91 (2.92)

Perceived Norms

12.55 (3.18)

MTC Norms

8.86 (3.50)

Perceived Behavioral Control

19.88 (3.37)

Structural Equation Model
Structural equation modeling was performed using maximum likelihood estimation to test
the overall fit of attitudes towards HPV vaccination, HPV vaccination norms, and perceived
behavioral control over HPV vaccination as predictors of HPV vaccination intentions. Structural
equation modeling allows a researcher to compare a tested model’s observed variance/covariance
matrix to an implied variance/covariance matrix (e.g., the theory of planned behavior model),
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which allows for a test of how well the theoretical model fits the given data. Results from the
structural equation model are presented in Figure 4.

Figure 4. Structural equation model of the theory of planned behavior
To understand the unique impact of the separate TPB constructs (e.g., behavioral beliefs
vs. general attitudes), separate latent constructs were estimated for each, and were correlated
with each other in the final model. The data were not multivariate normal (Mardia’s coefficient =
131.76 ≥ 31.08), however as a Bollen – Stine bootstrap procedure was performed, this nonnormality should not bias the results of the structural equation model. The model provided
adequate overall fit to the data [Bollen - Stine χ2 = 341.30, df = 195, p = .02, CFI = .934, TLI =
.922, RMSEA = .057]. The significant χ2 value indicates a misspecification in the comparison of
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the observed and reproduced variance/covariance matrix. However, the CFI and TLI values were
both above .90, with an RMSEA confidence interval containing a lower end value less than .05
(90% RMSEA CI: .047, .066). Considering these fit statistics, we argue that the TPB provides an
adequate overall fit to the data. The model indicated many significant correlations among the
latent predictors of HPV vaccination intentions. These correlations are presented in Table 9.
Table 9.
Correlations among the latent constructs.
Latent Construct
1. BehBeliefs

BehBeliefs

Attitudes

Norms

MTC

PBC

1

2. Attitudes

-.09

1

3. Norms

.62***

-.18*

1

4. MTC

.18*

-.10

.07

5. PBC

.38***

-.14

.36***

1

.08

1

______________________________________________________________________________
Standardized covariance estimates among latent predictors in the model
Note: BehBeliefs = Behavioral beliefs, MTC = Motivations to comply with norms, PBC =
Perceived behavioral control
N = 235. *p < .05, ***p < .001
There were significant correlations between norms and behavioral beliefs, indicating that
those who perceived greater social norms towards HPV vaccination were more likely to feel that
vaccination would produce a beneficial outcome (r = .62, p < .001). Norms were also negatively
correlated with attitudes towards HPV vaccination, suggesting that those who had negative
attitudes towards HPV vaccination perceived HPV vaccination as less normative (r = -.18, p =
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.02). Motivations to comply with norms did not correlate with perceived norms (r = .07, p = .37),
supporting the notion that norms and motivations to comply with those norms are separate
constructs. However, motivations to comply with norms were positively associated with
behavioral beliefs (r = .18, p = .02). This indicates that that those who value norms about HPV
vaccination may in turn believe that vaccination will produce a favorable outcome for them.
In the final model, perceived behavioral control was not associated with intentions to
vaccinate with the HPV vaccine; perceived behavioral control was, however, positively
associated with both behavioral beliefs (r = .38, p < .001) and perceived norms (r = .36, p <
.001). These results indicate that those who perceived greater social norms towards HPV
vaccination were also more likely to see vaccination as more normative. With the full model
being estimated with adequate fit, the parameters indicate that the sole predictor of intentions to
receive the HPV vaccine in the next 6 months was behavioral beliefs [β = .288, p = .005].
Exploratory Analyses: HPV vaccination
Exploratory analyses were performed to examine demographic differences in those who
have received the HPV vaccine. Out of the 267 participants who completed the survey, 26
(9.7%) stated that they received the HPV vaccine when asked the question “Have you ever
received the Gardasil vaccine?”
A chi-square analysis was performed to examine if there were racial differences in those
who received the HPV vaccine, for which there were no differences observed χ2 = 5.64, df = 4, p
= .23. Furthermore, gay and bisexual men did not differ from heterosexual men in terms of
having already received the HPV vaccine χ2 = 0.49, df = 2, p = .78. When relationship status was
submitted to a chi-square analysis, no differences emerged between persons in a relationship or
single, χ2 = 2.02, df = 3, p = .57. An additional question that simply asked “Are you sexually
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active?” was used in a chi-square analysis to examine differences between having been
vaccinated with Gardasil or not, to which no differences emerged, χ2 = 0.83, df = 2, p = .66. An
exploratory question asked participants if any person in their family had ever had cancer, with
56.9% indicated “yes”, 32.6% indicating “no”, 10.5% indicating “do not know”. Those who
indicated a family history of cancer were significantly more likely to report having received the
HPV vaccine (13.8%) than those who did not report such family history (5.7%), χ2 = 7.47, df = 2,
p = .02, in addition to indicating “false” on a question that stated “HPV is a woman’s disease”
(response options were true, false, or don’t know), χ2 = 11.07, df = 4, p = .03. The question
examining HPV as a woman’s disease, however, was unrelated to intentions to receive the HPV
vaccine among the unvaccinated, F(2,264) = 0.82, p = .92.
Discussion
The present study was the first to my knowledge to test the TPB in relation to male HPV
vaccination with all of its correct theoretical predictors. Result from this study furthers the
understanding of male intention to receive the HPV vaccine.
Hypothesis 1: Normality
The first hypothesis examined the normality of vaccination intentions. Given that HPV
vaccination is relatively new for men, there are concerns that there may be a lack of normality in
intentions to receive the HPV vaccine. Results from this study showed that the HPV vaccination
item was normally distributed, and furthermore provide support for past research which has
found significant results while using similar HPV vaccination items (Reiter et al., 2011; Daley et
al., 2011; Daley et al., 2010).
Hypothesis 2: Race
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The second hypothesis sought to examine racial variability in intentions to receive the
HPV vaccine. The test results suggest that the only difference observed was between white and
“other” races. With only 6.4% of the sample identifying as “Other” race, these differences are
difficult to interpret. Pragmatically, they mean that those who identified as “Other” had greater
intentions towards receiving the HPV vaccine than whites. This means that those who may be
mixed race or identify as an unmeasured race in this study have greater intentions towards
receive the HPV vaccine in the next 6 months.
Research has documented what is called the “White male effect” (Finucane, Slovic,
Flynn, & Satterfield, 2000), which posits that White males tend to perceive their subjective risk
as lower than that of non-whites. This “White male effect” defines risk perception more
generally, but can be applied to the results herein. While there were no differences in HPV
vaccination intentions among the other races measured (e.g., African-American, Hispanic,
Asian-American), the differences between Whites and “other” races may support the White male
effect in this instance.
Hypothesis 3: Sexual Orientation
The third hypothesis was to examine differences in vaccination intentions as a function of
sexual orientation. Past research suggests that gay and bisexual men have more positive attitudes
towards the HPV vaccine (Gilbert et al., 2011b), and greater knowledge about HPV, as well as
greater perceived likelihood of contracting HPV (Gilbert et al., 2011b). Results from this sample
do not support the hypothesis that there are differences in vaccination intentions between sexual
orientation groups. While gay and bisexual men had slightly higher means than heterosexual
men, these means were not statistically different from the means of the heterosexuals in this
sample. These results should be interpreted cautiously due to a low variability in sexual
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orientation in our sample. Only 8% of our unvaccinated sample identified as gay or bisexual, and
with the large number of individuals identifying as straight, there may not have been enough
power to detect differences in intention to receive the HPV vaccine.
To further investigate this issue of small variability in sexual orientation, the Cohen’s d
values indicated that the difference between bisexual and heterosexual men indicated a small
effect (.42 > .2), which suggests that bisexual men may have greater intentions to receive the
HPV vaccine when compared to heterosexual men. The effect size for the differences between
gay and heterosexual men did not reach the threshold of .2, so the assumption remains that gay
men and straight men are similar in their intentions to receive the HPV vaccine. When gay and
bisexual men were combined into one category, there was a small effect of the mean difference
between the two groups (d = .34), resulting in non-heterosexuals (gay and bisexual men)
potentially having greater intentions to receive the HPV vaccine when we consider the effect
size.
Hypothesis 4: Sexual Behavior
Past research has shown that having more sexual partners is associated with greater
willingness to receive the HPV vaccine, and a greater acceptance of that vaccine (Gerend et al.,
2008; Jones & Cook, 2008; Ferris et al., 2009). No past research to our knowledge has examined
how sexual behavior is associated with intentions to receive the HPV vaccine. However, past
research has identified positive relationships between sexual behavior and willingness to receive
the vaccine, as well as acceptance of the vaccine. Results from the present study showed that the
spearman’s rho correlation between the number of sexual partners in the past 3 months and HPV
vaccination intentions was not statistically significant. Furthermore, our exploratory analysis that
examined if sexually active individuals were significantly more likely to already have received
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the vaccine was not significant. Given that acceptance and willingness to receive the HPV
vaccine may be a completely separate construct from actual intention to receive the vaccine
could explain this non-significant result. However, it would be reasonable to assume that
willingness and acceptance would be highly correlated. Given that intentions involve a specific
behavioral component, intentions may represent a conceptual departure from constructs like
acceptance and willingness to receive the vaccine. As multiple studies have established a
relationship between sexual behavior and HPV vaccine willingness/acceptance, the remaining
explanation could be that men who have greater sexual partners may very well be willing to
receive the HPV vaccine, and think that getting the vaccine is acceptable, but may not actually
want to put the effort into getting the vaccine for themselves.
This result provides fruitful areas for future research, as there may be many different
statistical results when framing questions about HPV vaccination intention. Whether or not
someone accepts a vaccine, or is willing to receive it, may not indicate that they are intending to
receive the vaccine. Intentions require an active action on the part of the behavioral agent (the
individual), and may therefore be a different construct.
Hypothesis 5: Media influence
The research examining media influence on HPV vaccination intentions in males is
scarce. Results from the present study suggest that both influence from HPV commercials, as
well as using media for health information, were uncorrelated with intentions to receive the HPV
vaccine. DiClemente and colleagues (2011) provided initial support for this hypothesis when
their experiment on media influence indicated that any type of media advertisement targeting
men increased male intentions to receive the HPV vaccine. This could bolster the argument that
HPV vaccination may be more normative now, and that men may no longer see the HPV vaccine
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as a “Women’s issue” as a result of media advertisements heavily focusing on women. However,
more recent advertisements have been geared towards men and participants in this study may
have been exposed to those.
Hypothesis 6: TPB Model
Using our combination of CHIAS measures (McRee et al., 2010) and items modeled after
a sample TPB survey (Ajzen, 2012), the TPB provided an adequate fit to the data. One curious
finding that arose in examining the correlations among the latent constructs in the model was that
perceived behavioral control was correlated with perceived norms and behavioral beliefs in such
a way that suggests greater belief that getting the HPV vaccine would produce favorable
outcomes, along with greater perceived norms towards receiving the HPV vaccine, were
associated with greater perceived ability to receive the HPV vaccine. These relationships are all
in the expected directions. Of note is the especially strong relationship between behavioral
beliefs and perceived norms. The beta coefficient was .62 (p < .001), suggesting that men who
perceive greater norms of HPV vaccination are more likely to believe that it is beneficial for
them to receive the vaccine.
Other interesting results from the correlations among the TPB predictors illustrate that
norms and behavioral beliefs are highly correlated. This illustrates that norms and behavioral
beliefs may affect each other, such that those who perceive HPV vaccination as more normative
may also believe that HPV vaccination will produce favorable outcomes, or vise-versa. A weak
relationship was found between norms and attitudes, suggesting that those with greater perceived
HPV vaccination norms had less negative attitudes towards HPV vaccination. Moreover, an
equally weak relationship was found between motivations to comply with norms and behavioral
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beliefs, suggesting that those who value social norms in general are more likely to believe HPV
vaccination will produce a favorable outcome for them.
The model illustrated that the sole predictor of intentions to receive the HPV vaccine was
behavioral beliefs. Again, behavioral beliefs represent the idea that engaging in a behavior (in
this case, vaccination with the HPV vaccine) will produce a favorable given outcomes (e.g.,
protecting other partners, making oneself more healthy, etc.). This would indicate that the most
powerful predictor of whether a male vaccinates with the HPV vaccine would be whether he
believes doing so would be a good idea for his personal health. While surprising that no other
predictors on the TPB model were significant, it may make sense given that this sample
contained all men. Men are often not the targets of HPV vaccine advertisements, and the CDC
has only recently recommended that men receive the vaccine. As such, perceived norms towards
male vaccination may simply not be established yet among this sample. As a potential result of
this, motivations to comply with norms were also not a significant predictor of intentions to
receive the HPV vaccine. Attitudes toward HPV vaccination were measured using a previously
validated measure (the CHIAS; McRee et al., 2010), which theoretically mapped onto attitudes
towards HPV vaccination. This relationship between attitudes towards HPV vaccination and
intentions to receive the HPV vaccine was not significant, which may illustrate that men simply
may not utilize how they feel about the HPV vaccine when making judgments as to whether or
not they will receive the vaccine. Interestingly enough, Gerend & Shepherd (2012) found the
exact same beta coefficient for attitudes towards vaccination in their SEM model of the TPB
with women [β = .09, p < .05], which may suggest that there is an effect of attitudes on
vaccination intentions, but our sample size precluded us from detecting it. Alternatively, men
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may see behaviors like vaccination as generally necessary and may not care about whether or not
they have negative attitudes towards this specific health behavior.
The final construct of the TPB model that did not significantly predict HPV vaccination
intentions was perceived behavioral control. It may at first remain relatively puzzling that this
factor did not predict HPV vaccination intentions, especially as perceived behavioral control
tends to be among the strongest predictors in most TPB models (e.g., Gerend & Shepherd, 2012;
Norman & Cooper, 2011). A study by Crosby and colleagues (2011) found that self-efficacy to
be vaccinated with the HPV vaccine was not predictive of intentions to receive the vaccine.
Furthermore, a study by Hernandez and colleagues (2010) included a variable in their analysis of
male HPV vaccination intentions that asked participants whether transportation to a clinic to
receive the vaccine would influence intentions; this also was not significant in their final
analysis. Along with the results of the present study, it may suggest that perceived behavioral
control may not be a crucial factor in predicting HPV vaccination intentions among men. The
TPB argues that whether or not an individual engages in a health behavior is dependent on
whether one believes one is able to engage in that behavior (Ajzen, 2002). The alternative
explanation would be that whether or not a man believes he is able to get the HPV vaccine is
irrelevant in the subsequent intentions to receive the HPV vaccine. The perception of vaccination
may be different from that of other health behaviors, like quitting smoking or negotiating safer
sex. Receiving the HPV vaccine may be perceived as relatively easy, and so an immense amount
of self-efficacy may not be needed to actually intend to receive it.
Exploratory analyses
Our exploratory analyses were performed to examine demographic factors that were
associated with having already received the HPV vaccine. These results suggest that no one
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demographic factor predicted HPV vaccination: sexual orientation, race, sexual activity, and
relationship status. The sole demographic factor that was predictive of HPV vaccination was
having a family history of cancer. This result ties in well with the results of the structural
equation model, which suggests that behavioral beliefs are the sole predictor of HPV vaccination
intentions. Those who have a family history of cancer may be high in the behavioral belief that
vaccination will benefit them, because the perceived threat of them getting cancer at some point
in the future is high.
Previous research on family histories of cancer has illustrated that women with a family
history of cancer are more likely to receive a pap test (Williams, Reiter, Mabiso, Maurer, &
Paskett, 2009). In this study, just having a family history of cancer was powerful enough for
these women to receive a pap test, which is important for HPV detection. A similar finding was
found in a male sample for prostate, colorectal, and skin cancer screenings. Shah and colleagues
(2007) found that men who had a family history of prostate, colorectal, and skin cancer were
significantly more likely to report receiving an examination coinciding with their family history;
these results were stronger for young men.
Past research shows that there is a powerful impact of having a family history of cancer
in terms of engaging in preventative measures to reduce the risk of cancer. Much in the same
way, our data support these studies by showing that young men with a family history of cancer
were more likely to report receiving the HPV vaccine. These vaccination behaviors could be
potentially due to a doctor’s suggestion, or increased knowledge about HPV. The latter may be
true given that men in this study who had a family history of cancer were also significantly more
likely to indicate “false” on a question that stated “HPV is a woman’s disease”, suggesting that
those who have been vaccinated may be more knowledgeable about male HPV risks.
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Limitations
The present study had several limitations. Of these were cross-sectional data precluding
any ability at causal inference. Secondly, the data presented in this study did not actually record
whether or not participants received the HPV vaccine at a later time, which may have very well
occurred and limits the full examination of the TPB model.
One major limitation in this study was that testing the TPB requires the researcher to
create items to test the appropriate constructs. As such, the items used to test the most of the TPB
model were created for the purpose of testing the TPB model. To make this process more
stringent and nested within past studies, we often looked to past research to find appropriate
constructs (e.g., using the CHIAS to estimate some constructs of the TPB, and a sample
questionnaire). While EFA was performed to retain the best fitting items, it could be argued that
a sample-specific model was fit and estimated based on EFA item retention.
While that may be true when estimating factor fit per construct (e.g., perceived norms,
attitudes towards vaccination separately), it is not entirely plausible when testing the full
theoretical model. This is due to items not being deleted based on poor factor loading when
testing the full structural equation model, but when estimating each individual factor. As items
were not retained to maximize the final model fit in the final model, but were deleted while
performing a factor analysis on each individual construct before testing the final model, it
provides a relatively stringent way of testing model fit in a single cross-sectional sample.
This study employed a relatively small sample size. Through factor analysis we
eliminated poorly fitting items, which reduced needless parameter estimates, and improved
power. Moreover, the use of a Bollen – Stine bootstrapping technique corrects for small sample
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size and non-normality, which should eliminate any negative impact of a small sample size when
testing the full model.
The model that we posit only had adequate fit, as the RMSEA value was greater than .05.
The chi-square statistic was significant, indicating a significant misspecification of the observed
and reproduced variance/covariance matrix. Furthermore, the CFI and TLI values were above
.90, but less than .95, which indicate adequate fit. Finally, the RMSEA value was greater than the
suggested .05 cutoff value. However, since the 90% confidence interval contained .05 as an
estimate of model fit, it is presumptuous to reject the model altogether.
The data from the current sample were derived from a majority (50.6%) white sample,
which may preclude extrapolation of interpretation beyond this group. Post hoc analysis revealed
that there were no significant differences between whites and non-whites in their intentions to
receive the HPV vaccine in the next 6 months.
General Implications
While this study had limitations, it also provides insight into how the TPB fits when
predicting college-aged male’s HPV vaccination intentions. An implication of the present study
is that theoretical models may not work best when predicting health behaviors (e.g., vaccination)
which may not be viewed as necessary or essential by certain groups (e.g., men); therefore,
testing theoretical models may not provide the best predictors of behavior in populations who do
not see themselves at risk. Future studies should consider performing comparisons of theoretical
models of HPV vaccination between genders. As found by Gerend and Shepherd (2011), the
TPB was a fitting model for predicting HPV vaccination intentions for female participants,
outperforming the HBM in terms of model fit. The present research suggests that males may be
different from females in terms of how they decide on whether or not to receive the HPV
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vaccine. As such, a specific avenue for future research would be to test and compare models of
behavior change (e.g., TPB, HBM, transtheoretical model) and see how, alone or in combination,
these models better predict HPV vaccination.
Some have argued that the TPB assumes that the individual is an informed agent of their
own behavior change. Other TPB examples may highlight weight loss or beginning an exercise
regimen as a health behavior to measure, however those health behaviors are commonly taken up
across genders, and one could assume that participants would know that exercise or weight loss
might benefit them regardless of their individual gender. In the instance of HPV, men may not be
acting as informed agents, and therefore only behavioral beliefs remained as a predictor of HPV
vaccination intentions in my sample. In other words, if men do not see themselves at risk for
HPV, then the TPB model may provide an adequate model of predicting behavioral intentions.
This highlights the importance of behavioral beliefs in predicting male HPV vaccination
intentions, and provides important information to physicians and interventionists attempting to
increase HPV vaccination among males, by emphasizing the health benefits of HPV vaccination.
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